65 6 Literaturverzeichnis 1. Abd El-Rehim DM, Pinder SE et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 91 (8): 1532-1542, 2004. 2. Allred DC, Clark GM et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23 (9): 974-979, 1992. 3. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 410 (1): 8386, 1997. 4. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol 19 (18 Suppl): 32S-40S, 2001. 5. Bacus SS, Chin D et al. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. Am J Pathol 148 (2): 549-558, 1996. 6. Baselga J, Albanell J et al. Mechanism of action of trastuzumab and scientific update. Semin Oncol 28 (5 Suppl 16): 4-11, 2001. 7. Baselga J, Mendelsohn J. Receptor blockade with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther 64 (1): 127-154, 1994. 8. Baselga J, Tripathy D et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14 (3): 737-744, 1996. 9. Battaglia F, Scambia G et al. Epidermal growth factor receptor in human breast cancer: correlation with steroid hormone receptors and axillary lymph node involvement. Eur J Cancer Clin Oncol 24 (11): 1685-1690, 1988. 10. Bell R. What can we learn from Herceptin trials in metastatic breast cancer? Oncology 63 Suppl 1: 39-46, 2002. 11. Birner P, Oberhuber G et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7 (6): 1669-1675, 2001. 12. Busmanis I, Feleppa F et al. Analysis of cerbB2 expression using a panel of 6 commercially available antibodies. Pathology 26 (3): 261-267, 1994. 13. Carlomagno C, Perrone F et al. c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol 14 (10): 2702-2708, 1996. 66 14. Carter P, Presta L et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89 (10): 4285-4289, 1992. 15. Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15 (2 Suppl 1): 20-25, 1988. 16. Clark GM, Sledge GW, Jr. et al. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5 (1): 55-61, 1987. 17. Clarke RB, Howell A et al. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 57 (22): 4987-4991, 1997. 18. Clynes RA, Towers TL et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6 (4): 443-446, 2000. 19. Cobleigh MA, Vogel CL et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17 (9): 2639-2648, 1999. 20. Cohen S, Taylor JM. Epidermal growth factor: chemical and biological characterization. Recent Prog Horm Res 30 (0): 533-550, 1974. 21. Costa S, Stamm H et al. Predictive value of EGF receptor in breast cancer. Lancet 2 (8622): 1258, 1988. 22. Cowley SM, Parker MG. A comparison of transcriptional activation by ER α and ER β. J Steroid Biochem Mol Biol 69 (1-6): 165-175, 1999. 23. Dabrosin C, Margetts PJ, Gauldie J. Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. Int J Cancer 107 (4): 535540, 2003. 24. DAKO HercepTest: A Manual for Interpretation. DAKO: 2000. 25. Damjanov I, Mildner B, Knowles BB. Immunohistochemical localization of the epidermal growth factor receptor in normal human tissues. Lab Invest 55 (5): 588-592, 1986. 26. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 8 (3): 191-195, 2001. 27. Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 2 (3): 273-277, 1988. 28. Drebin JA, Link VC, Greene MI. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2 (4): 387-394, 1988. 29. Drebin JA, Link VC et al. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41 (3): 697-706, 1985. 67 30. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (9114): 1451-1467, 1998. 31. Edgerton SM, Moore D et al. erbB-2 (HER-2) and breast cancer progression. Appl Immunohistochem Mol Morphol 11 (3): 214-221, 2003. 32. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term followup. Histopathology 19 (5): 403-410, 1991. 33. Esteva FJ, Hortobagyi GN et al. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol Oncol Res 7 (3): 171-177, 2001. 34. Fendly BM, Winget M et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50 (5): 1550-1558, 1990. 35. Ferlay J, Bray F et al. GLOBOCAN 2000: Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No 5 IARC Press (Version 1.0): 2001. 36. Fletcher SW, Colditz GA. Failure of estrogen plus progestin therapy for prevention. JAMA 288 (3): 366-368, 2002. 37. Foekens JA, Portengen H et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 49 (24 Pt 1): 7002-7009, 1989. 38. Fuchs IB, Loebbecke M et al. HER2 in brain metastases: issues of concordance, survival, and treatment. J Clin Oncol 20 (19): 4130-4133, 2002. 39. Fuchs IB, Siemer I et al. Epidermal growth factor receptor changes during breast cancer metastasis. Anticancer Res 26 (6B): 4397-4401, 2006. 40. Fuqua SA. The role of estrogen receptors in breast cancer metastasis. J Mammary Gland Biol Neoplasia 6 (4): 407-417, 2001. 41. Fuqua SA, Wiltschke C et al. A hypersensitive estrogen receptor-α mutation in premalignant breast lesions. Cancer Res 60 (15): 4026-4029, 2000. 42. Gancberg D, Di Leo A et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 13 (7): 1036-1043, 2002. 43. Gasparini G, Gullick WJ et al. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma – an immunocytochemical study. Eur J Cancer 30A (1): 16-22, 1994. 44. Gilbertson RJ, Perry RH et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57 (15): 3272-3280, 1997. 68 45. Goldhirsch A, Glick JH et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 19 (18): 3817-3827, 2001. 46. Goldstein NI, Prewett M et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 (11): 13111318, 1995. 47. Graus-Porta D, Beerli RR et al. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16 (7): 1647-1655, 1997. 48. Grimaux M, Romain S et al. Prognostic value of epidermal growth factor receptor in nodepositive breast cancer. Breast Cancer Res Treat 14 (1): 77-90, 1989. 49. Gullick WJ, Marsden JJ et al. Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas. Cancer Res 46 (1): 285-292, 1986. 50. Gullick WJ, Srinivasan R. The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer. Breast Cancer Res Treat 52 (1-3): 43-53, 1998. 51. Gustafsson JA. Estrogen receptor β – a new dimension in estrogen mechanism of action. J Endocrinol 163 (3): 379-383, 1999. 52. Gusterson B, Cowley G et al. Cellular localisation of human epidermal growth factor receptor. Cell Biol Int Rep 8 (8): 649-658, 1984. 53. Gusterson BA, Gelber RD et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10 (7): 10491056, 1992. 54. Guy CT, Webster MA et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci U S A 89 (22): 10578-10582, 1992. 55. Guy PM, Platko JV et al. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 91 (17): 8132-8136, 1994. 56. Hancock MC, Langton BC et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51 (17): 4575-4580, 1991. 57. Harris LN, Liotcheva V et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 19 (6): 16981706, 2001. 58. Harvey JM, Clark GM et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17 (5): 1474-1481, 1999. 59. Hendler FJ, Ozanne BW. Human squamous cell lung cancers express increased epidermal growth factor receptors. J Clin Invest 74 (2): 647-651, 1984. 69 60. Heppner GH. Tumor cell societies. J Natl Cancer Inst 81 (9): 648-649, 1989. 61. Hudelist G, Singer CF et al. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat 80 (3): 353-361, 2003. 62. Hudziak RM, Lewis GD et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9 (3): 1165-1172, 1989. 63. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 84 (20): 7159-7163, 1987. 64. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198 (2-3): 165-184, 1994. 65. Iwao K, Miyoshi Y et al. Quantitative analysis of estrogen receptor-β mRNA and its variants in human breast cancers. Int J Cancer 88 (5): 733-736, 2000. 66. Izumi Y, Xu L et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416 (6878): 279-280, 2002. 67. Jacobs TW, Gown AM et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17 (7): 1983-1987, 1999. 68. Jacobs TW, Prioleau JE et al. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 88 (15): 1054-1059, 1996. 69. John HA, Birnstiel ML, Jones KW. RNA-DNA hybrids at the cytological level. Nature 223 (206): 582-587, 1969. 70. Kainulainen V, Sundvall M et al. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J Biol Chem 275 (12): 8641-8649, 2000. 71. Karayiannakis AJ, Bastounis EA et al. Immunohistochemical detection of oestrogen receptors in ductal carcinoma in situ of the breast. Eur J Surg Oncol 22 (6): 578-582, 1996. 72. Kato S, Masuhiro Y et al. Molecular mechanism of a cross-talk between oestrogen and growth factor signalling pathways. Genes Cells 5 (8): 593-601, 2000. 73. Kerbel RS. Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res 55: 87-132, 1990. 74. Kew TY, Bell JA et al. c-erbB-4 protein expression in human breast cancer. Br J Cancer 82 (6): 1163-1170, 2000. 75. Khan SA, Rogers MA et al. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90 (1): 37-42, 1998. 70 76. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13 (6): 506-513, 2001. 77. Klapper LN, Kirschbaum MH et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77: 25-79, 2000. 78. Klijn JG, Berns PM et al. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13 (1): 3-17, 1992. 79. Knight WA, Livingston RB et al. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37 (12): 4669-4671, 1977. 80. Knowlden JM, Gee JM et al. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 17 (15): 1949-1957, 1998. 81. Koenders PG, Beex LV et al. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group. Breast Cancer Res Treat 18 (1): 27-32, 1991. 82. Konecny G, Pauletti G et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95 (2): 142-153, 2003. 83. Kraus MH, Issing W et al. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. Proc Natl Acad Sci U S A 86 (23): 9193-9197, 1989. 84. Kurebayashi J, Okubo S et al. Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast Cancer 11 (1): 38-41, 2004. 85. Kuukasjarvi T, Karhu R et al. Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. Cancer Res 57 (8): 15971604, 1997. 86. Kuukasjarvi T, Kononen J et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 14 (9): 2584-2589, 1996. 87. Lane HA, Beuvink I et al. ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 20 (9): 3210-3223, 2000. 88. Lane HA, Motoyama AB et al. Modulation of p27/Cdk2 complex formation through 4D5mediated inhibition of HER2 receptor signaling. Ann Oncol 12 Suppl 1: S21-S22, 2001. 89. Lawson JS, Field AS et al. Low oestrogen receptor α expression in normal breast tissue underlies low breast cancer incidence in Japan. Lancet 354 (9192): 1787-1788, 1999. 90. Leal CB, Schmitt FC et al. Ductal carcinoma in situ of the breast. Histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53, and c-erbB-2 protein. Cancer 75 (8): 2123-2131, 1995. 71 91. Lebeau A, Deimling D et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19 (2): 354-363, 2001. 92. Lemoine NR, Barnes DM et al. Expression of the ERBB3 gene product in breast cancer. Br J Cancer 66 (6): 1116-1121, 1992. 93. Levkowitz G, Klapper LN et al. Coupling of the c-Cbl protooncogene product to ErbB1/EGF-receptor but not to other ErbB proteins. Oncogene 12 (5): 1117-1125, 1996. 94. Lewis GD, Figari I et al. Differential responses of human tumor cell lines to antip185HER2 monoclonal antibodies. Cancer Immunol Immunother 37 (4): 255-263, 1993. 95. Lewis S, Locker A et al. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol 43 (5): 385-389, 1990. 96. Leygue E, Dotzlaw H et al. Altered estrogen receptor α and β messenger RNA expression during human breast tumorigenesis. Cancer Res 58 (15): 3197-3201, 1998. 97. Leygue E, Hall RE et al. Oestrogen receptor-α variant mRNA expression in primary human breast tumours and matched lymph node metastases. Br J Cancer 79 (5-6): 978-983, 1999. 98. Lichtner RB. Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies. Biomed Pharmacother 57 (10): 447-451, 2003. 99. Livingston RB, Esteva FJ. Chemotherapy and herceptin for HER2(+) metastatic breast cancer: the best drug? Oncologist 6 (4): 315-316, 2001. 100. Lodge AJ, Anderson JJ et al. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J Clin Pathol 56 (4): 300-304, 2003. 101. Longy M, Duboue B et al. Method for the purification of tissue DNA suitable for PCR after fixation with Bouin's fluid. Uses and limitations in microsatellite typing. Diagn Mol Pathol 6 (3): 167-173, 1997. 102. Macias A, Azavedo E et al. Receptors for epidermal growth factor in human mammary carcinomas and their metastases. Anticancer Res 6 (4): 849-851, 1986. 103. Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 30 (3): 259265, 2000. 104. Mass R, Sanders C, Kasian C. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in Herceptin(R) pivotal trials. Proc Am Soc Clin Oncol 19 (75a): 2000. 105. McKenzie SJ, Marks PJ et al. Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185. Oncogene 4 (5): 543-548, 1989. 72 106. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 19 (56): 6550-6565, 2000. 107. Molina MA, Codony-Servat J et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61 (12): 4744-4749, 2001. 108. Moreno A, Lloveras B et al. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers. Mod Pathol 10 (11): 1088-1092, 1997. 109. Naidu R, Yadav M et al. Expression of c-erbB3 protein in primary breast carcinomas. Br J Cancer 78 (10): 1385-1390, 1998. 110. Nass SJ, Dickson RB. Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat 44 (1): 1-22, 1997. 111. Newby JC, Johnston SR et al. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res 3 (9): 1643-1651, 1997. 112. Nicholson RI, Hutcheson IR et al. Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer. Endocr Relat Cancer 8 (3): 175-182, 2001. 113. Niehans GA, Singleton TP et al. Stability of HER-2/neu expression over time and at multiple metastatic sites. J Natl Cancer Inst 85 (15): 1230-1235, 1993. 114. Padhy LC, Shih C et al. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 28 (4): 865-871, 1982. 115. Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev 8 (2): 98-101, 1989. 116. Pallis L, Wilking N et al. Receptors for estrogen and progesterone in breast carcinoma in situ. Anticancer Res 12 (6B): 2113-2115, 1992. 117. Pardue ML, Gall JG. Molecular hybridization of radioactive DNA to the DNA of cytological preparations. Proc Natl Acad Sci U S A 64 (2): 600-604, 1969. 118. Pauletti G, Dandekar S et al. Assessment of methods for tissue-based detection of the HER2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 18 (21): 3651-3664, 2000. 119. Pauletti G, Godolphin W et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13 (1): 63-72, 1996. 120. Pawlowski V, Revillion F et al. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6 (11): 4217-4225, 2000. 73 121. Pedersen MW, Meltorn M et al. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 12 (6): 745760, 2001. 122. Penault-Llorca F, Adelaide J et al. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol 173 (1): 65-75, 1994. 123. Plowman GD, Culouscou JM et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci U S A 90 (5): 1746-1750, 1993. 124. Plowman GD, Whitney GS et al. Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. Proc Natl Acad Sci U S A 87 (13): 49054909, 1990. 125. Polosa R, Prosperini G et al. Expression of c-erbB receptors and ligands in human bronchial mucosa. Am J Respir Cell Mol Biol 20 (5): 914-923, 1999. 126. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5 (7): 953-962, 1990. 127. Press MF, Hung G et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 54 (10): 2771-2777, 1994. 128. Quinn CM, Ostrowski JL et al. c-erbB-3 protein expression in human breast cancer: comparison with other tumour variables and survival. Histopathology 25 (3): 247-252, 1994. 129. Rajkumar T, Gooden CS et al. Expression of the c-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1. J Pathol 170 (3): 271-278, 1993. 130. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers – a review. Gene 159 (1): 19-27, 1995. 131. Ravdin PM, Green S et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10 (8): 1284-1291, 1992. 132. Rennstam K, Baldetorp B et al. Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. Cancer Res 61 (3): 1214-1219, 2001. 133. Ricketts D, Turnbull L et al. Estrogen and progesterone receptors in the normal female breast. Cancer Res 51 (7): 1817-1822, 1991. 134. Rios MA, Macias A et al. Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res 8 (1): 173-176, 1988. 74 135. Robertson JF. Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer 73 (1): 5-12, 1996. 136. Roger P, Sahla ME et al. Decreased expression of estrogen receptor β protein in proliferative preinvasive mammary tumors. Cancer Res 61 (6): 2537-2541, 2001. 137. Ross JS, Fletcher JA. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist 3 (4): 237-252, 1998. 138. Rossouw JE, Anderson GL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (3): 321-333, 2002. 139. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol 12 Suppl 1: S3-S8, 2001. 140. Sainsbury JR, Malcolm AJ et al. Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 38 (11): 1225-1228, 1985. 141. Salomon DS, Brandt R et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 (3): 183-232, 1995. 142. Sartor CI, Zhou H et al. Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 21 (13): 4265-4275, 2001. 143. Sawyer C, Hiles I et al. Two erbB-4 transcripts are expressed in normal breast and in most breast cancers. Oncogene 17 (7): 919-924, 1998. 144. Seidman AD, Fornier MN et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19 (10): 2587-2595, 2001. 145. Shimizu C, Fukutomi T et al. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues. J Surg Oncol 73 (1): 17-20, 2000. 146. Shoker BS, Jarvis C et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. Am J Pathol 155 (6): 1811-1815, 1999. 147. Slamon D. Herceptin: increasing survival in metastatic breast cancer. Eur J Oncol Nurs 4 (Sa): 24-29, 2000. 148. Slamon DJ, Clark GM et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 (4785): 177-182, 1987. 149. Slamon DJ, Godolphin W et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 (4905): 707-712, 1989. 150. Slamon DJ, Leyland-Jones B et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344 (11): 783-792, 2001. 75 151. Sliwkowski MX, Lofgren JA et al. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26 (4 Suppl 12): 60-70, 1999. 152. Smith CL. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod 58 (3): 627-632, 1998. 153. Speirs V, Kerin MJ. Prognostic significance of oestrogen receptor β in breast cancer. Br J Surg 87 (4): 405-409, 2000. 154. Spyratos F, Ferrero-Pous M et al. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer 94 (8): 2151-2159, 2002. 155. Srinivasan R, Benton E et al. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 α, neuregulin-1 β, and betacellulin, in normal endometrium and endometrial cancer. Clin Cancer Res 5 (10): 2877-2883, 1999. 156. Srinivasan R, Gillett CE et al. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. Cancer Res 60 (6): 1483-1487, 2000. 157. Srinivasan R, Poulsom R et al. Expression of the c-erbB-4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types. J Pathol 185 (3): 236-245, 1998. 158. Stabenow R, Eisinger B. Brustkrebs. Epidemiologische Daten zum weiblichen Brustkrebs aus dem Gemeinsamen Krebsregister der Länder Berlin, Brandenburg, MecklenburgVorpommern, Sachsen-Anhalt und der Freistaaten Sachsen und Thüringen. Schriftenreihe des GKR 1: 2001. 159. Stal O, Sullivan S et al. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer 31A (13-14): 2185-2190, 1995. 160. Stancovski I, Hurwitz E et al. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci U S A 88 (19): 8691-8695, 1991. 161. Stoica A, Saceda M et al. Regulation of estrogen receptor-α gene expression by epidermal growth factor. J Endocrinol 165 (2): 371-378, 2000. 162. Suo Z, Berner HS et al. Estrogen receptor-α and C-ERBB-4 expression in breast carcinomas. Virchows Arch 439 (1): 62-69, 2001. 163. Suo Z, Emilsen E et al. Type 1 protein tyrosine kinases in benign and malignant breast lesions. Histopathology 33 (6): 514-521, 1998. 164. Suo Z, Risberg B et al. EGFR family expression in breast carcinomas. c-erbB-2 and cerbB-4 receptors have different effects on survival. J Pathol 196 (1): 17-25, 2002. 165. Tang CK, Concepcion XZ et al. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res 59 (20): 5315-5322, 1999. 76 166. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIα in primary and metastatic breast cancer. Cancer Res 61 (14): 5345-5348, 2001. 167. Taylor JM, Mitchell WM, Cohen S. Characterization of the binding protein for epidermal growth factor. J Biol Chem 249 (7): 2188-2194, 1974. 168. Taylor JM, Mitchell WM, Cohen S. Characterization of the high molecular weight form of epidermal growth factor. J Biol Chem 249 (10): 3198-3203, 1974. 169. Tovey SM, Witton CJ et al. Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. Breast Cancer Res 6 (3): R246-R251, 2004. 170. Travis A, Pinder SE et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer 74 (2): 229-233, 1996. 171. Tsuda H, Hirohashi S et al. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 49 (11): 3104-3108, 1989. 172. Tsuda H, Iwaya K et al. p53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade. Jpn J Cancer Res 84 (4): 394-401, 1993. 173. Tsutsui S, Kataoka A et al. Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res 8 (11): 3454-3460, 2002. 174. Tzahar E, Waterman H et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16 (10): 5276-5287, 1996. 175. Ullrich A, Coussens L et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309 (5967): 418-425, 1984. 176. Vladusic EA, Hornby AE et al. Expression of estrogen receptor β messenger RNA variant in breast cancer. Cancer Res 58 (2): 210-214, 1998. 177. Vogel CL, Cobleigh MA et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 61 Suppl 2: 37-42, 2001. 178. Vogel CL, Cobleigh MA et al. Efficacy and safety of trastuzumab as a single agent in firstline treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20 (3): 719726, 2002. 179. Vogt U, Bielawski K et al. Amplification of erbB-4 oncogene occurs less frequently than that of erbB-2 in primary human breast cancer. Gene 223 (1-2): 375-380, 1998. 180. von Minckwitz G, Brunnert K et al. Evidenz-basierte Empfehlungen zur Behandlung von lokoregionär und fernmetastasierten Mammakarzinomen. Zentralbl Gynakol 124 (5): 293303, 2002. 77 181. Walker RA, Camplejohn RS. DNA flow cytometry of human breast carcinomas and its relationship to transferrin and epidermal growth factor receptors. J Pathol 150 (1): 37-42, 1986. 182. Witton CJ, Reeves JR et al. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200 (3): 290-297, 2003. 183. Wright C, Nicholson S et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 65 (1): 118-121, 1992. 184. Yakes FM, Chinratanalab W et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62 (14): 4132-4141, 2002. 185. Yang XD, Jia XC et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 38 (1): 17-23, 2001. 186. Yang XD, Jia XC et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59 (6): 1236-1243, 1999. 187. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 61 Suppl 2: 113, 2001. 188. Yokota J, Yamamoto T et al. Amplification of c-erbB-2 oncogene in human adenocarcinomas in vivo. Lancet 1 (8484): 765-767, 1986. 189. Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Bioessays 22 (7): 673680, 2000. 190. Zhou W, Carpenter G. ErbB-4: a receptor tyrosine kinase. Inflamm Res 51 (2): 91-101, 2002.
© Copyright 2018